Nicox - Commercial products continue to grow
Nicox published a third quarter operational update on 19 October and provided new prescriptions uptake data for its two commercial-stage out-licensed products, Vyzulta and Zerviate. Nicox reported that the number of US prescriptions for Vyzulta rose by 35% y-o-y in Q321 and for Zerviate the increase was 213% y-o-y. Net royalties increased by c €0.1m q-o-q to €0.7m. The company also reiterated recent guidance on the progress of its key internal programmes, including the reporting of primary efficacy data for the Mont Blanc NCX-470 Phase III study in Q123.Nicox is engaged in the ophthalmic market. Co. markets several ophthalmic products in the United States and Europe with a portfolio of therapies and diagnostic tools that can help people to enhance their sight. Co. has developed naproxcinod, the first member of the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, for the treatment of the signs and symptoms of osteoarthritis. Beyond naproxcinod, Co. has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.